| scholarly article | Q13442814 |
| P50 | author | Simon Wilkins | Q55537273 |
| Ashley I. Bush | Q39880503 | ||
| P2093 | author name string | J L George | |
| S Mok | |||
| D I Finkelstein | |||
| R A Cherny | |||
| D Moses | |||
| P2860 | cites work | Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis | Q22242250 |
| Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase | Q22254584 | ||
| A role for alpha-synuclein in the regulation of dopamine biosynthesis | Q24293727 | ||
| Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability | Q24299939 | ||
| Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis | Q24304952 | ||
| Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism | Q24309753 | ||
| Hereditary early-onset Parkinson's disease caused by mutations in PINK1 | Q24337084 | ||
| Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. | Q24535854 | ||
| Relation between aluminum concentrations in drinking water and Alzheimer's disease: an 8-year follow-up study | Q24644989 | ||
| Occupational exposures to solvents and aluminium and estimated risk of Alzheimer's disease | Q24672121 | ||
| Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27 | Q24680250 | ||
| Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models | Q24683059 | ||
| Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein | Q26269955 | ||
| Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase | Q27649733 | ||
| Crystal structure of tyrosine hydroxylase at 2.3 A and its implications for inherited neurodegenerative diseases | Q27740782 | ||
| Crystal structure of tyrosine hydroxylase with bound cofactor analogue and iron at 2.3 A resolution: self-hydroxylation of Phe300 and the pterin-binding site | Q27765365 | ||
| Mutation in the alpha-synuclein gene identified in families with Parkinson's disease | Q27860459 | ||
| alpha-Synuclein locus triplication causes Parkinson's disease | Q27860533 | ||
| Alpha-synuclein in Lewy bodies | Q27860680 | ||
| Staging of brain pathology related to sporadic Parkinson's disease | Q28131702 | ||
| Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology | Q28131833 | ||
| Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease | Q28187904 | ||
| Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat | Q28215248 | ||
| Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor | Q28237467 | ||
| Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease | Q28292932 | ||
| Mapping of a gene for Parkinson's disease to chromosome 4q21-q23 | Q28295005 | ||
| Improvement of abnormal pyruvate metabolism and cardiac conduction defect with coenzyme Q10 in Kearns-Sayre syndrome | Q28307882 | ||
| Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease | Q28317593 | ||
| "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy | Q28317866 | ||
| Influence of neuromelanin on oxidative pathways within the human substantia nigra | Q34802086 | ||
| Techniques for gene transfer into neurons. | Q34942440 | ||
| Mutational analysis of DJ-1 in Drosophila implicates functional inactivation by oxidative damage and aging | Q34944292 | ||
| Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain | Q35000819 | ||
| Neural transplantation for the treatment of Parkinson's disease | Q35172255 | ||
| Parkinson's disease: is the initial treatment established? | Q35203983 | ||
| Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease | Q35213394 | ||
| Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation | Q35490116 | ||
| The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. | Q35626716 | ||
| Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model | Q35747138 | ||
| The relevance of iron in the pathogenesis of Parkinson's disease. | Q35754511 | ||
| A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation | Q35761478 | ||
| Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons | Q35786982 | ||
| Metals in our minds: therapeutic implications for neurodegenerative disorders | Q35811065 | ||
| Placebo mechanisms and reward circuitry: clues from Parkinson's disease. | Q35825195 | ||
| Superoxide accelerates DNA damage by elevating free-iron levels | Q35921515 | ||
| Regional dissection and determination of loosely bound and non-heme iron in the developing mouse brain | Q35962705 | ||
| 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of parkinson's disease, with emphasis on mice and nonhuman primates. | Q35969693 | ||
| Is levodopa toxic? | Q36022114 | ||
| Copper, beta-amyloid, and Alzheimer's disease: tapping a sensitive connection | Q36160457 | ||
| PINK1 mutation heterozygosity and the risk of Parkinson's disease | Q36227281 | ||
| Imaging of calcium and aluminum in neurofibrillary tangle-bearing neurons in parkinsonism-dementia of Guam | Q36256318 | ||
| Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease | Q36288717 | ||
| Prospective study of dietary pattern and risk of Parkinson disease | Q36426202 | ||
| The neurotoxicity of amphetamines: bridging drugs of abuse and neurodegenerative disorders. | Q36469891 | ||
| A new look at levodopa based on the ELLDOPA study | Q36611595 | ||
| Complex I, iron, and ferritin in Parkinson's disease substantia nigra | Q36730657 | ||
| Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia | Q36739461 | ||
| NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded | Q36830682 | ||
| In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining | Q36857701 | ||
| Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. | Q36880531 | ||
| A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. | Q36880536 | ||
| Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease | Q36895132 | ||
| Redox imbalance in Parkinson's disease | Q36899782 | ||
| Aluminum but not iron treatment induces pro-oxidant events in the rat brain | Q41664962 | ||
| Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. | Q41953550 | ||
| Decreased ferritin levels in brain in Parkinson's disease | Q42000755 | ||
| Pigmentation in the nucleus substantiae nigrae of mammals. | Q42112197 | ||
| Copper(II)-induced self-oligomerization of alpha-synuclein. | Q42158800 | ||
| Comparative resistance of the 20S and 26S proteasome to oxidative stress. | Q42159087 | ||
| Effects of flavonoids on Naja naja and human recombinant synovial phospholipases A2 and inflammatory responses in mice. | Q42285800 | ||
| Neuroferritinopathy: a window on the role of iron in neurodegeneration. | Q42436187 | ||
| Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats | Q42436464 | ||
| Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains | Q42477389 | ||
| Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. | Q42492136 | ||
| Aluminum-induced neurofibrillary degeneration affects a subset of neurons in rabbit cerebral cortex, basal forebrain and upper brainstem | Q42498358 | ||
| Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation | Q42501526 | ||
| Pathophysiology of L-dopa-induced abnormal involuntary movements | Q42507094 | ||
| An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. | Q42524820 | ||
| Chronic low-Ca/Mg high-Al diet induces neuronal loss | Q42527569 | ||
| Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. | Q42617687 | ||
| Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid | Q42620617 | ||
| Exposure to aluminium and the subsequent development of a disorder with features of Alzheimer's disease | Q42765223 | ||
| Genetic analysis of families with Parkinson disease that carry the Ala53Thr mutation in the gene encoding alpha-synuclein | Q43218554 | ||
| Water quality has a pronounced effect on cholesterol-induced accumulation of Alzheimer amyloid beta (Abeta) in rabbit brain. | Q43359935 | ||
| Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers. | Q43619529 | ||
| Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease | Q43624453 | ||
| Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron | Q43640204 | ||
| Failure to find a relationship between mnestic skills of octogenarians and aluminum in drinking water | Q43646719 | ||
| Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson's disease | Q43668015 | ||
| 6-hydroxydopamine-induced nuclear factor-kappa B activation in PC12 cells. | Q43670369 | ||
| A polymorphic variation of serine to tyrosine at codon 18 in the ubiquitin C-terminal hydrolase-L1 gene is associated with a reduced risk of sporadic Parkinson's disease in a Japanese population | Q43727689 | ||
| Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration | Q43735211 | ||
| Nitration and inactivation of tyrosine hydroxylase by peroxynitrite | Q43759048 | ||
| The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein | Q43798526 | ||
| Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures | Q43832105 | ||
| Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms | Q43849066 | ||
| Overexpression of human alpha-synuclein causes dopamine neuron death in primary human mesencephalic culture | Q43868527 | ||
| Effects of aluminum and zinc on the oxidative stress caused by 6-hydroxydopamine autoxidation: relevance for the pathogenesis of Parkinson's disease. | Q43963316 | ||
| Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures | Q44027697 | ||
| Proteasome inhibition causes nigral degeneration with inclusion bodies in rats | Q44094584 | ||
| Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism. The European Consortium on Genetic Susceptibility in Parkinson's Disease and the French Parkinson's Disease Genetics Study Gro | Q44182363 | ||
| Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats | Q44183832 | ||
| Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. | Q44187776 | ||
| Vitamin E supplements fail to protect mice from acute MPTP neurotoxicity. | Q44215292 | ||
| Aggresome-related biogenesis of Lewy bodies | Q44242992 | ||
| Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. | Q44264439 | ||
| Altered proteasomal function in sporadic Parkinson's disease | Q44264446 | ||
| Neurotoxic effects of aluminium among foundry workers and Alzheimer's disease | Q44273876 | ||
| Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease | Q44386905 | ||
| Cocaine abusers have an overexpression of alpha-synuclein in dopamine neurons. | Q44396203 | ||
| Movement disorders in the Hfe knockout mouse | Q44452286 | ||
| Adult nutrient intake as a risk factor for Parkinson's disease | Q44487546 | ||
| Manganese, copper, and zinc in cerebrospinal fluid from patients with multiple sclerosis | Q44497674 | ||
| Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications | Q44511146 | ||
| A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease | Q44571920 | ||
| Genetic analysis of LRRK2 mutations in patients with Parkinson disease | Q46857317 | ||
| Effects of pallidotomy on motor symptoms in an animal model of Parkinson's disease | Q46889281 | ||
| Drosophila DJ-1 mutants are sensitive to oxidative stress and show reduced lifespan and motor deficits | Q47072826 | ||
| Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. | Q47831483 | ||
| UCHL1 is a Parkinson's disease susceptibility gene | Q47866612 | ||
| The ubiquitin pathway in Parkinson's disease | Q48015939 | ||
| Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications | Q48088787 | ||
| Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. | Q48144142 | ||
| Peroxynitrite induces tryosine nitration and modulates tyrosine phosphorylation of synaptic proteins | Q48148974 | ||
| Iron and other metals in neuromelanin, substantia nigra, and putamen of human brain | Q48164667 | ||
| Histochemical and X-ray microanalytical localization of aluminum in amyotrophic lateral sclerosis and parkinsonism-dementia of Guam | Q48167005 | ||
| Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease | Q48168351 | ||
| Alpha-tocopherol and beta-carotene do not protect marmosets against the dopaminergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine | Q48189797 | ||
| High dose levodopa therapy is not toxic in multiple system atrophy: experimental evidence | Q48207785 | ||
| MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects | Q48228911 | ||
| Monoamine oxidase, hydrogen peroxide, and Parkinson's disease. | Q48254031 | ||
| Biochemical pathophysiology of Parkinson's disease. | Q48258284 | ||
| Expression of ferritin protein and subunit mRNAs in normal and iron deficient rat brain | Q48270964 | ||
| Brain iron in the rat: extremely slow turnover in normal rats may explain long-lasting effects of early iron deficiency | Q48288693 | ||
| Chronic rotenone treatment induces behavioral effects but no pathological signs of parkinsonism in mice | Q48336800 | ||
| Unilateral subthalamotomy in the treatment of Parkinson's disease | Q48338772 | ||
| Total and paramagnetic metals in human substantia nigra and its neuromelanin | Q48367595 | ||
| Growth of transplanted monoaminergic neurones into the adult hippocampus along the perforant path | Q48369614 | ||
| Nigrostriatal damage with 6-OHDA: validation of routinely applied procedures | Q48369923 | ||
| Oral administration of metal chelator ameliorates motor dysfunction after a small hemorrhage near the internal capsule in rat. | Q48388799 | ||
| Possible regeneration of gamma-aminobutyric acid-containing fibres into irides transplanted into the central nervous system | Q48402514 | ||
| M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease. | Q48405800 | ||
| Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study | Q48419227 | ||
| Role of manganese in dystonia | Q48419648 | ||
| Iron- and manganese-catalyzed autoxidation of dopamine in the presence of L-cysteine: possible insights into iron- and manganese-mediated dopaminergic neurotoxicity | Q48427127 | ||
| Ascorbic acid reduces the dopamine depletion induced by MPTP. | Q48432320 | ||
| Effects of chronic methamphetamine on the nigral-striatal dopamine system in rat brain: tyrosine hydroxylase immunochemistry and quantitative light microscopic studies | Q48434326 | ||
| Postnatal iron overload destroys NA-DA functional interactions | Q48437217 | ||
| Actions of 6-hydroxydopamine quinones on catecholamine neurons | Q48438065 | ||
| Gastrointestinal absorption of aluminium and citrate in man. | Q48448209 | ||
| Chronic ferritin expression within murine dopaminergic midbrain neurons results in a progressive age-related neurodegeneration. | Q48449992 | ||
| Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain | Q48450630 | ||
| Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease | Q48450930 | ||
| Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse | Q48452041 | ||
| Uptake and distribution of iron and transferrin in the adult rat brain. | Q48459489 | ||
| Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity | Q48463677 | ||
| PARK7 DJ-1 protects against degeneration of nigral dopaminergic neurons in Parkinson's disease rat model | Q48465219 | ||
| Aluminium salts accelerate peroxidation of membrane lipids stimulated by iron salts | Q48468985 | ||
| Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice | Q48482071 | ||
| Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients | Q48489167 | ||
| 4-hydroxynonenal, a lipid peroxidation product, impairs glutamate transport in cortical astrocytes. | Q48490623 | ||
| Increasing striatal iron content associated with normal aging | Q48491547 | ||
| Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron | Q48491695 | ||
| Genetic vitamin E deficiency does not affect MPTP susceptibility in the mouse brain | Q48492232 | ||
| Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. | Q48502457 | ||
| The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity | Q64777142 | ||
| Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients | Q64778242 | ||
| Microstimulation-induced inhibition of neuronal firing in human globus pallidus | Q64779027 | ||
| Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease | Q64821269 | ||
| Synthetic carotenoids, novel polyene polyketones and new capsorubin isomers as efficient quenchers of singlet molecular oxygen | Q68188283 | ||
| Immunological and biochemical studies and pilot therapeutic trial with ubidecarenone in Kearns-Sayre patients | Q68247909 | ||
| Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide | Q68255434 | ||
| Clinical and biochemical correlations in mitochondrial myopathies treated with coenzyme Q10 | Q68352956 | ||
| Monoamine oxidase and oxidative stress at dopaminergic synapses | Q68382268 | ||
| Positron emission tomography in manganese intoxication | Q69248608 | ||
| Comparison of the regional distribution of transferrin receptors and aluminium in the forebrain of chronic renal dialysis patients | Q69429374 | ||
| Role of dopamine in manganese neurotoxicity | Q69850146 | ||
| Induction of DNA breakage and suppression of DNA synthesis by the OH radical generated in a Fenton-like reaction | Q70139579 | ||
| A brainstem atlas of catecholaminergic neurons in man, using melanin as a natural marker | Q70765260 | ||
| Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal | Q70831530 | ||
| Dietary lipids and antioxidants in Parkinson's disease: a population-based, case-control study | Q70928225 | ||
| 4-Hydroxynonenal triggers Ca2+ influx in isolated rat hepatocytes | Q70946276 | ||
| Mapping of the gracile axonal dystrophy (gad) gene to a region between D5Mit197 and D5Mit113 on proximal mouse chromosome 5 | Q71739707 | ||
| Polyphenolic flavanols as scavengers of aqueous phase radicals and as chain-breaking antioxidants | Q71778889 | ||
| Lipid peroxidation and changes in the ubiquinone content and the respiratory chain enzymes of submitochondrial particles | Q71939401 | ||
| The correlation between active oxygens scavenging and antioxidative effects of flavonoids | Q72150971 | ||
| Relations between tocopherol depletion and coenzyme Q during lipid peroxidation in rat liver mitochondria | Q72177081 | ||
| Intranigral injected iron progressively reduces striatal dopamine metabolism | Q72232437 | ||
| Bromocriptine scavenges methamphetamine-induced hydroxyl radicals and attenuates dopamine depletion in mouse striatum | Q72438789 | ||
| Activated oxygen species at the origin of chromosome breakage and sister-chromatid exchanges | Q72921258 | ||
| MR evaluation of age-related increase of brain iron in young adult and older normal males | Q73184477 | ||
| Antioxidant and prooxidant behavior of flavonoids: structure-activity relationships | Q73268875 | ||
| Role of oxidative stress in the manganese and 1-methyl-4-(2'-ethylphenyl)-1,2,3,6-tetrahydropyridine-induced apoptosis in PC12 cells | Q73504495 | ||
| Absorption of aluminium-26 in Alzheimer's disease, measured using accelerator mass spectrometry | Q73516357 | ||
| Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies | Q73626218 | ||
| Impaired proteasome function in Alzheimer's disease | Q73897101 | ||
| Oligodendrocyte progenitor cells internalize ferritin via clathrin-dependent receptor mediated endocytosis | Q73911882 | ||
| Axonal sprouting following lesions of the rat substantia nigra | Q73947220 | ||
| Association between a polymorphism of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) gene and sporadic Parkinson's disease | Q74016935 | ||
| Neuropathology in mice expressing human alpha-synuclein | Q74139704 | ||
| Peroxynitrite-mediated inactivation of manganese superoxide dismutase involves nitration and oxidation of critical tyrosine residues | Q74248716 | ||
| Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model | Q28344741 | ||
| Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice | Q28505777 | ||
| Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine | Q28510205 | ||
| Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice | Q28510424 | ||
| alpha-Synuclein produces a long-lasting increase in neurotransmitter release | Q28510893 | ||
| Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein | Q28511573 | ||
| Manganese superoxide dismutase mediates the early release of mitochondrial cytochrome C and subsequent DNA fragmentation after permanent focal cerebral ischemia in mice | Q28588544 | ||
| Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons | Q28590748 | ||
| Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. | Q28593258 | ||
| Antioxidant functions of vitamins. Vitamins E and C, beta-carotene, and other carotenoids | Q28609442 | ||
| Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data | Q28943545 | ||
| The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia | Q29547174 | ||
| Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy | Q29614178 | ||
| Alpha-synuclein locus duplication as a cause of familial Parkinson's disease | Q29614762 | ||
| Chronic systemic pesticide exposure reproduces features of Parkinson's disease | Q29614763 | ||
| Why are "natively unfolded" proteins unstructured under physiologic conditions? | Q29615739 | ||
| Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin | Q29617063 | ||
| Transplantation of embryonic dopamine neurons for severe Parkinson's disease | Q29617304 | ||
| Oxidative stress and neurodegeneration: where are we now? | Q29617324 | ||
| Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes | Q29617606 | ||
| The 26S proteasome: a molecular machine designed for controlled proteolysis | Q29619692 | ||
| The E46K mutation in alpha-synuclein increases amyloid fibril formation. | Q30349931 | ||
| Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice | Q30764264 | ||
| L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function | Q30837835 | ||
| Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct | Q31029246 | ||
| Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein | Q31120123 | ||
| Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections | Q31457974 | ||
| Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult | Q31961798 | ||
| Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice | Q33215982 | ||
| Antioxidants protect PINK1-dependent dopaminergic neurons in Drosophila | Q33255660 | ||
| Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease | Q33260250 | ||
| Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson' | Q33260251 | ||
| Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia | Q33322579 | ||
| Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease | Q33323265 | ||
| Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon | Q33735320 | ||
| Evaluation of surgery for Parkinson's disease: a report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. The Task Force on Surgery for Parkinson's Disease | Q33795694 | ||
| Effects on the nervous system among welders exposed to aluminium and manganese | Q33819551 | ||
| Environmental exposure to trace elements and risk of amyotrophic lateral sclerosis: a population-based case-control study | Q74477216 | ||
| Effect of plant flavonoids on immune and inflammatory cell function | Q77440716 | ||
| Induction of DNA strand breakage and base oxidation by nitroxyl anion through hydroxyl radical production | Q77919964 | ||
| Aluminum enhances melanin-induced lipid peroxidation | Q78230739 | ||
| Toward identification of susceptibility genes for sporadic Parkinson's disease | Q79209570 | ||
| DJ-1( PARK7), a novel gene for autosomal recessive, early onset parkinsonism | Q79249169 | ||
| A common A340T variant in PINK1 gene associated with late-onset Parkinson's disease in Chinese | Q79329781 | ||
| Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation | Q79796313 | ||
| The 5'-untranslated region of Parkinson's disease alpha-synuclein messengerRNA contains a predicted iron responsive element | Q79838827 | ||
| CuZn-SOD deficiency causes ApoB degradation and induces hepatic lipid accumulation by impaired lipoprotein secretion in mice | Q80142989 | ||
| Case-control study of UCHL1 S18Y variant in Parkinson's disease | Q80187773 | ||
| Alpha-synuclein overexpression increases cytosolic catecholamine concentration | Q80223133 | ||
| Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease | Q80794093 | ||
| Levodopa and the progression of Parkinson's disease | Q81595933 | ||
| Selegiline slows the progression of the symptoms of Parkinson disease | Q82843497 | ||
| Differential involvement of mitochondrial permeability transition in cytotoxicity of 1-methyl-4-phenylpyridinium and 6-hydroxydopamine | Q83178182 | ||
| Striatal FP-CIT uptake differs in the subtypes of early Parkinson's disease | Q48529629 | ||
| Bilateral pallidotomy in Parkinson's disease: a retrospective study | Q48552730 | ||
| Distribution of paraquat into the brain after its systemic injection in rats. | Q48563982 | ||
| Glutathione deficiency potentiates manganese toxicity in rat striatum and brainstem and in PC12 cells. | Q48566534 | ||
| Intranuclear aluminum accumulation in chronic animals with experimental neurofibrillary changes | Q48648073 | ||
| Iron deposits in multiple sclerosis and Alzheimer's disease brains | Q48682014 | ||
| Can cocaine abuse cause parkinsonism? | Q48739953 | ||
| Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease | Q48774077 | ||
| Intracerebral grafting of neuronal cell suspensions. II. Survival and growth of nigral cell suspensions implanted in different brain sites. | Q48828178 | ||
| Intracerebral grafting of neuronal cell suspensions. VIII. Survival and growth of implants of nigral and septal cell suspensions in intact brains of aged rats | Q48828185 | ||
| Intracerebral grafting of neuronal cell suspensions. VII. Recovery of choline acetyltransferase activity and acetylcholine synthesis in the denervated hippocampus reinnervated by septal suspension implants | Q48828193 | ||
| Intracerebral grafting of neuronal cell suspensions. VI. Survival and growth of intrahippocampal implants of septal cell suspensions | Q48828203 | ||
| Intracerebral grafting of neuronal cell suspensions. I. Introduction and general methods of preparation. | Q48828219 | ||
| Intracerebral grafting of neuronal cell suspensions. V. Behavioural recovery in rats with bilateral 6-OHDA lesions following implantation of nigral cell suspensions | Q48829640 | ||
| Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease | Q48830095 | ||
| Treatment of mice with methamphetamine produces cell loss in the substantia nigra | Q48887098 | ||
| Diet and Parkinson's disease. I: A possible role for the past intake of specific foods and food groups. Results from a self-administered food-frequency questionnaire in a case-control study | Q48935400 | ||
| Neonatal iron potentiates adult MPTP-induced neurodegenerative and functional deficits | Q48952359 | ||
| Correspondence of melanin-pigmented neurons in human brain with A1-A14 catecholamine cell groups | Q48973700 | ||
| Variations in dietary iron alter behavior in developing rats | Q49069501 | ||
| Influence of age on the passage of paraquat through the blood-brain barrier in rats: a distribution and pathological examination | Q49075919 | ||
| Neurobehavioral dysfunctions associated with dietary iron overload | Q49129846 | ||
| Stimulation of the subthalamic nucleus in a patient with Parkinson disease and essential tremor | Q49157981 | ||
| The natural history of neurological manganism over 18 years | Q50277880 | ||
| Dietary iron, animal fats, and risk of Parkinson's disease. | Q50884333 | ||
| Dietary antioxidants and Parkinson disease. The Rotterdam Study. | Q50950498 | ||
| EXPERIMENTAL PRODUCTION OF NEUROFIBRILLARY DEGENERATION. I. LIGHT MICROSCOPIC OBSERVATIONS | Q51253309 | ||
| Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments. | Q51943432 | ||
| Dietary antioxidants and other dietary factors in the etiology of Parkinson's disease. | Q52003162 | ||
| Cognitive deficits in iron-deficient and iron-deficient anemic children. | Q52078963 | ||
| Inactivation of dehydratase [4Fe-4S] clusters and disruption of iron homeostasis upon cell exposure to peroxynitrite. | Q52527681 | ||
| Membrane binding and self-association of alpha-synucleins. | Q52543652 | ||
| Aluminum exposure and risk of Alzheimer disease. | Q53223016 | ||
| Aluminum forms in drinking water and risk of Alzheimer's disease. | Q53343948 | ||
| Mechanism for manganese enhancement of dopamine-induced oxidative DNA damage and neuronal cell death. | Q53606465 | ||
| The role of pathogenic DJ-1 mutations in Parkinson's disease. | Q54757155 | ||
| Parkinson's disease | Q56877819 | ||
| 3-Hydroxykynurenine and 3-Hydroxyanthranilic Acid Generate Hydrogen Peroxide and Promote α-Crystallin Cross-Linking by Metal Ion Reduction† | Q57080763 | ||
| The iron-responsive element is the single element responsible for iron-dependent translational regulation of ferritin biosynthesis. Evidence for function as the binding site for a translational repressor | Q57397579 | ||
| Copper- and iron-induced differential fibril formation in α-synuclein: TEM study | Q57459956 | ||
| Thermodynamics imprinting reveals differential binding of metals to α-synuclein: Relevance to parkinson’s disease | Q57459960 | ||
| A heterozygous effect for PINK1 mutations in Parkinson's disease? | Q58617948 | ||
| Functional reactivation of the deafferented neostriatum by nigral transplants | Q59067439 | ||
| Degeneration of the centré median-parafascicular complex in Parkinson's disease | Q59544666 | ||
| Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain | Q61714016 | ||
| Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine | Q64764588 | ||
| An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. | Q64768245 | ||
| No tissue damage by chronic deep brain stimulation in Parkinson's disease | Q64770078 | ||
| Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease | Q37671552 | ||
| DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite | Q37700756 | ||
| Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease | Q37713838 | ||
| Carotenoids, tocopherols and thiols as biological singlet molecular oxygen quenchers | Q37796068 | ||
| Role of catechol autooxidation in the degeneration of dopamine neurons | Q37971848 | ||
| Mitochondrial membrane depolarization and the selective death of dopaminergic neurons by rotenone: protective effect of coenzyme Q10. | Q38514050 | ||
| Dietary factors in Parkinson's disease: the role of food groups and specific foods | Q38547790 | ||
| Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels | Q39097283 | ||
| Presynaptic and postsynaptic striatal dopaminergic function in patients with manganese intoxication: a positron emission tomography study | Q39114810 | ||
| Hereditary form of parkinsonism--dementia | Q39116097 | ||
| Efficacy of bilateral subthalamic nucleus (STN) stimulation in Parkinson's disease | Q39359246 | ||
| Success and problems of long-term levodopa therapy in Parkinson's disease | Q39419773 | ||
| MPTP-induced deficits in striatal synaptic plasticity are prevented by glial cell line-derived neurotrophic factor expressed via an adeno-associated viral vector. | Q40095787 | ||
| Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease | Q40201129 | ||
| RNA interference-mediated knockdown of alpha-synuclein protects human dopaminergic neuroblastoma cells from MPP(+) toxicity and reduces dopamine transport. | Q40203572 | ||
| GDNF reduces oxidative stress in a 6-hydroxydopamine model of Parkinson's disease | Q40204577 | ||
| Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. | Q40216832 | ||
| Parkin affects mitochondrial function and apoptosis in neuronal and myogenic cells | Q40244264 | ||
| Clioquinol and docosahexaenoic acid act synergistically to kill tumor cells. | Q40246736 | ||
| GDNF in Parkinson disease: an object lesson in the tyranny of type II. | Q40250019 | ||
| Androgen and anti-androgen treatment modulates androgen receptor activity and DJ-1 stability | Q40284570 | ||
| Influence of different promoters on the expression pattern of mutated human alpha-synuclein in transgenic mice. | Q40297921 | ||
| Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model | Q40320292 | ||
| Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi | Q40321534 | ||
| Parkin enhances mitochondrial biogenesis in proliferating cells | Q40322753 | ||
| Clinical trials with rasagiline: evidence for short-term and long-term effects | Q40323136 | ||
| The pathogenesis of cell death in Parkinson's disease | Q40323146 | ||
| Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease | Q40326219 | ||
| 6-hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta | Q40339108 | ||
| Effect of overexpression of wild-type or mutant parkin on the cellular response induced by toxic insults | Q40380055 | ||
| Role of RNA secondary structure of the iron-responsive element in translational regulation of ferritin synthesis | Q40396368 | ||
| Effect of AdGDNF on dopaminergic neurotransmission in the striatum of 6-OHDA-treated rats | Q40427208 | ||
| Anticancer activity of the antibiotic clioquinol | Q40434343 | ||
| Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease | Q40442685 | ||
| Effects of DJ-1 mutations and polymorphisms on protein stability and subcellular localization | Q40442695 | ||
| Role of mitochondria in neuronal cell death induced by oxidative stress; neuroprotection by Coenzyme Q10. | Q40449016 | ||
| Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation. | Q40524258 | ||
| Effects of 6-hydroxydopamine on primary cultures of substantia nigra: specific damage to dopamine neurons and the impact of glial cell line-derived neurotrophic factor | Q40566456 | ||
| Oxidative stress regulated genes in nigral dopaminergic neuronal cells: correlation with the known pathology in Parkinson's disease | Q40672194 | ||
| Alpha-synuclein lowers p53-dependent apoptotic response of neuronal cells. Abolishment by 6-hydroxydopamine and implication for Parkinson's disease | Q40694627 | ||
| Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line | Q40714967 | ||
| Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease | Q40737427 | ||
| Pro-inflammatory effects of aluminum in human glioblastoma cells | Q40740789 | ||
| Long-term proliferation and dopaminergic differentiation of human mesencephalic neural precursor cells | Q40789736 | ||
| Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease | Q40795664 | ||
| Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration | Q40811477 | ||
| The causes of Parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality | Q40842068 | ||
| Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity | Q40844291 | ||
| Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease | Q40846012 | ||
| Immortalized dopamine neurons: A model to study neurotoxicity and neuroprotection | Q40918411 | ||
| Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease | Q40929764 | ||
| Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity | Q40956717 | ||
| Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation | Q40964871 | ||
| Identification and characterization of a novel protein that regulates RNA-protein interaction | Q40972571 | ||
| The lipid peroxidation product 4-hydroxynonenal impairs glutamate and glucose transport and choline acetyltransferase activity in NSC-19 motor neuron cells | Q40978148 | ||
| Glial cell line-derived neurotrophic growth factor inhibits apoptotic death of postnatal substantia nigra dopamine neurons in primary culture | Q41021656 | ||
| Differentiation of mesencephalic progenitor cells into dopaminergic neurons by cytokines | Q41059727 | ||
| Gastrointestinal absorption of aluminium in Alzheimer's disease: response to aluminium citrate. | Q41117220 | ||
| The history of iron in the brain | Q41144685 | ||
| Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae | Q41173089 | ||
| Efficient transduction of human neurons with an adeno-associated virus vector | Q41222907 | ||
| Selective vulnerability of glutathione metabolism and cellular defense mechanisms in rat striatum to manganese. | Q41347591 | ||
| Case-control study of early life dietary factors in Parkinson's disease | Q41405298 | ||
| Intraneuronal aluminum accumulation in amyotrophic lateral sclerosis and Parkinsonism-dementia of Guam | Q41624368 | ||
| Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy | Q41632791 | ||
| Intron-exon structure of ubiquitin c-terminal hydrolase-L1. | Q33853339 | ||
| Low frequency of pathogenic mutations in the ubiquitin carboxy-terminal hydrolase gene in familial Parkinson's disease | Q33858726 | ||
| Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. | Q33922930 | ||
| Alzheimer disease beta-amyloid activity mimics cholesterol oxidase | Q33925332 | ||
| Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis | Q34020005 | ||
| Preclinical (premotor) Parkinson's disease | Q34035624 | ||
| Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease | Q34049606 | ||
| Pathophysiology of the basal ganglia in Parkinson's disease. | Q34070859 | ||
| Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. | Q34082498 | ||
| Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. | Q34086208 | ||
| Impaired iron homeostasis in Parkinson's disease. | Q34155212 | ||
| The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility | Q34157005 | ||
| Histochemical observations on rodent brain melanin | Q34264554 | ||
| Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial | Q34283745 | ||
| Metabolism and function of coenzyme Q. | Q34294224 | ||
| In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia. | Q34316878 | ||
| Aluminium as a risk factor in Alzheimer's disease, with emphasis on drinking water | Q34317933 | ||
| Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease | Q34331409 | ||
| Identification of two distinct synucleins from human brain | Q34341909 | ||
| Novel PINK1 mutations in early-onset parkinsonism | Q34345898 | ||
| Progression after chronic manganese exposure | Q34352765 | ||
| Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease | Q34358956 | ||
| Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. | Q34361701 | ||
| Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease | Q34376115 | ||
| Aluminum concentrations in drinking water and risk of Alzheimer's disease | Q34422708 | ||
| Long-term progression in chronic manganism: ten years of follow-up | Q34461867 | ||
| Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline | Q34528059 | ||
| Functional effects of neuromelanin and synthetic melanin in model systems. | Q34534985 | ||
| Pesticide exposure and risk for Parkinson's disease | Q34542115 | ||
| Levodopa and the progression of Parkinson's disease | Q34553278 | ||
| Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism. | Q34584417 | ||
| Diet and Parkinson's disease. II: A possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study | Q34734597 | ||
| ??? | Q64767196 | ||
| ??? | Q64782380 | ||
| ??? | Q64786912 | ||
| ??? | Q64867043 | ||
| ??? | Q64976807 | ||
| Timecourse of striatal re-innervation following lesions of dopaminergic SNpc neurons of the rat. | Q44574098 | ||
| Do patients with Parkinson?s disease benefit from embryonic dopamine cell transplantation? | Q44632473 | ||
| Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease | Q44653423 | ||
| Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats | Q44697081 | ||
| How does Parkinson's disease begin? The role of compensatory mechanisms. | Q44809582 | ||
| Autoxidation and MAO-mediated metabolism of dopamine as a potential cause of oxidative stress: role of ferrous and ferric ions. | Q44843169 | ||
| Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats | Q44848373 | ||
| Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. | Q44856789 | ||
| A perspective on transplantation therapy and stem cells for Parkinson's disease | Q44931899 | ||
| Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid | Q44961994 | ||
| L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats | Q44987162 | ||
| Lipid rafts mediate the synaptic localization of alpha-synuclein. | Q44999245 | ||
| Inhibition of proteasome activity sensitizes dopamine neurons to protein alterations and oxidative stress | Q45104002 | ||
| Similarities between methamphetamine toxicity and proteasome inhibition. | Q45149968 | ||
| PCTH: a novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice. | Q45192666 | ||
| Prevalence of parkinsonism and relationship to exposure in a large sample of Alabama welders | Q45236735 | ||
| Subthalamic stimulation activates internal pallidus: evidence from cGMP microdialysis in PD patients. | Q45283166 | ||
| "Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease | Q45309188 | ||
| Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. | Q45711545 | ||
| Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector | Q45769447 | ||
| Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease | Q45881923 | ||
| Iron deprivation during fetal development changes the behavior of juvenile rhesus monkeys | Q46064657 | ||
| Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity | Q46070812 | ||
| Evidence for a partially folded intermediate in alpha-synuclein fibril formation | Q46097239 | ||
| MPTP toxicity in the mouse brain and vitamin E. | Q46306995 | ||
| Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration. | Q46377129 | ||
| Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. | Q46404063 | ||
| Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice | Q46440075 | ||
| Haloperidol treatment reverses behavioural and anatomical changes in cocaine-dependent mice | Q46443518 | ||
| Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease | Q46452329 | ||
| Role of oxidative stress in paraquat-induced dopaminergic cell degeneration. | Q46460372 | ||
| Acute or repeated cocaine administration generates reactive oxygen species and induces antioxidant enzyme activity in dopaminergic rat brain structures | Q46460578 | ||
| Postural changes after lesions of the substantia nigra pars reticulata in hemiparkinsonian monkeys. | Q46465349 | ||
| Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway | Q46537593 | ||
| Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration | Q46541429 | ||
| Hydrophobicity as the signal for selective degradation of hydroxyl radical-modified hemoglobin by the multicatalytic proteinase complex, proteasome | Q46557220 | ||
| Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia. | Q46589894 | ||
| A combinatorial code for the interaction of alpha-synuclein with membranes | Q46601588 | ||
| Regional distributions of manganese, iron, copper, and zinc in the brains of 6-hydroxydopamine-induced parkinsonian rats | Q46678106 | ||
| Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases | Q46682421 | ||
| Roles of Drosophila DJ-1 in survival of dopaminergic neurons and oxidative stress | Q46684001 | ||
| Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition | Q46718285 | ||
| Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion | Q46718289 | ||
| A slowly developing dysfunction of dopaminergic nigrostriatal neurons induced by long-term paraquat administration in rats: an animal model of preclinical stages of Parkinson's disease? | Q46725802 | ||
| Structure-property studies on the antioxidant activity of flavonoids present in diet. | Q46730721 | ||
| Drosophila DJ-1 mutants show oxidative stress-sensitive locomotive dysfunction. | Q46734652 | ||
| Dityrosine and tyrosine oxidation products are endogenous markers for the selective proteolysis of oxidatively modified red blood cell hemoglobin by (the 19 S) proteasome. | Q46736712 | ||
| Neural activity controls the synaptic accumulation of alpha-synuclein. | Q46832286 | ||
| P433 | issue | 1 | |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 9-36 | |
| P577 | publication date | 2009-03-01 | |
| P1433 | published in | Current Neuropharmacology | Q20181354 |
| P1476 | title | Targeting the progression of Parkinson's disease | |
| P478 | volume | 7 |
| Q51764192 | Animal Toxins as Therapeutic Tools to Treat Neurodegenerative Diseases. |
| Q55049102 | Aqueous Extract of Dendropanax morbiferus Leaves Effectively Alleviated Neuroinflammation and Behavioral Impediments in MPTP-Induced Parkinson's Mouse Model. |
| Q26829742 | Cellular models to investigate biochemical pathways in Parkinson's disease |
| Q58715913 | Characteristics of the mitochondrial and cellular uptake of MPP+, as probed by the fluorescent mimic, 4'I-MPP |
| Q45873810 | Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments |
| Q26765787 | Is Modulation of Oxidative Stress an Answer? The State of the Art of Redox Therapeutic Actions in Neurodegenerative Diseases |
| Q38981601 | Mathematical models of α-synuclein transport in axons |
| Q26772733 | Melatonin and Other Tryptophan Metabolites Produced by Yeasts: Implications in Cardiovascular and Neurodegenerative Diseases |
| Q96953438 | Mismatch Negativity and Impaired Social Functioning in Long-Term and in First Episode Schizophrenia Spectrum Psychosis |
| Q37764793 | Mitochondrial dysfunction in neurodegenerative diseases and cancer |
| Q34184725 | Molecular imaging of cell death in an experimental model of Parkinson's disease with a novel apoptosis-targeting peptide |
| Q38111373 | NADPH oxidase and neurodegeneration |
| Q44593403 | Neuroprotective effect of aqueous extract of Selaginella delicatula as evidenced by abrogation of rotenone-induced motor deficits, oxidative dysfunctions, and neurotoxicity in mice |
| Q37825631 | Parkinson's disease dementia and potential therapeutic strategies |
| Q46952414 | Polygalasaponin F against rotenone-induced apoptosis in PC12 cells via mitochondria protection pathway |
| Q34398474 | Predictive association of copper metabolism proteins with Alzheimer's disease and Parkinson's disease: a preliminary perspective |
| Q36946543 | Selective brain penetrable Nurr1 transactivator for treating Parkinson's disease |
| Q30512976 | Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson's disease |
| Q33556006 | Staging neurodegenerative disorders: structural, regional, biomarker, and functional progressions |
| Q92406209 | The Ameliorative Effects of the Ethyl Acetate Extract of Salicornia europaea L. and Its Bioactive Candidate, Irilin B, on LPS-Induced Microglial Inflammation and MPTP-Intoxicated PD-Like Mouse Model |
| Q89509387 | The Potential Role of Astrocytes in Parkinson's Disease (PD) |
| Q41497337 | The effect of red grape juice and exercise, and their combination on parkinson(')s disease in rats |
| Q39063048 | The novel tetramethylpyrazine bis-nitrone (TN-2) protects against MPTP/MPP+-induced neurotoxicity via inhibition of mitochondrial-dependent apoptosis |
Search more.